The incidence and mortality of cutaneous malignant melanoma (CMM) are increasing year by year among white people, but the incidence in China is very low, but due to the lack of awareness of its seriousness, it is usually too late when it is diagnosed. We only discuss the surgical and biological aspects of CMM. Treatment progress is reviewed as follows: The principle of CMM treatment is surgical excision of the primary focus. After resection of the primary lesion in stage I and II CMM, extensive lymph node dissection is still required for all sites where recurrence or metastasis is estimated to be possible. Stage IV surgical resection should include lesions in the skin, central nervous system, lungs and gastrointestinal tract, etc. Palliative resection not only reduces pain, but also can sometimes have unexpected effects in improving the quality of life and prolonging the survival of patients by simply removing distant lung metastases or subcutaneous recurrence. The scope of resection of primary foci Before the 1980s, the principle of wide resection was advocated in the surgical treatment of primary foci of CMM, and sometimes a wide resection of 5 cm from the primary foci was performed. With the improvement of the understanding of CMM and the improvement of the detection rate of early lesions, the principle of determining the extent of resection according to the thickness of the tumor was proposed. If the lesion is suspected to be CMM, the whole lesion together with the normal skin and subcutaneous fat of 0.5-1.0 cm around the lesion will be excised for pathological examination, and if it is confirmed to be CMM, the absolute vertical thickness of the thickest part of the tumor will be determined by direct measurement of the tumor with the eyepiece micrometer proposed by Breslow. If the tumor thickness is <1 mm, the resection margin should be 1 cm from the tumor margin; if the tumor thickness is 1-4 mm, the resection margin should be 2 cm; if the tumor thickness is >4 mm, the resection margin should be 3-5 cm; if the tumor thickness is located at the extremity of CMM, finger (toe) amputation is often required. The principle of restrictive resection is currently advocated, i.e., the extent of CMM resection should be limited to a margin of 1 to 3 cm. The depth of resection of the primary foci of CMM should be equal to the width of the minimum margin of resection of the primary foci, and it is still controversial whether the deep fascia of the tumor area should be resected or not, but for tumor invasion of skin thickness more than 4.10 mm, resection of the primary foci of CMM is recommended. The deep fascia of the tumor area is still controversial, but for tumor invasion of skin thickness more than 4.10 mm, the deep fascia should be removed. Biological treatment: 1, IFN2α and interleukin-2 (L2) are commonly used, 2, T-cell growth factor L2, tumor gene vaccine, etc. In recent years, dendritic cells (DC) vaccines have been favored as one of the most powerful antigen-presenting cells (APC) known, which can present antigens to T cells in vivo and externally, initiate and induce T cell differentiation to produce CTL responses or directly activate B cells and generate immune memory. With the advancement of DC research, the technology to obtain a large number of DCs in vitro and to prepare DC vaccines is becoming more sophisticated, especially for the preparation of DC vaccines specific to each patient. Thurner suggested that CMM vaccines prepared from DCs could frequently amplify CMM-specific CTL cells and induce regression of metastatic CMM lesions. The efficacy of DC vaccines sensitized with the tumor lysate keyhole hemocyanin (KLH) or antigenic peptides in the treatment of patients with advanced CMM has been achieved. As a specific cellular immunotherapy method, DC has the potential to become an indispensable adjunct in the field of tumor biotherapy in the near future because of its safe and non-toxic characteristics.